
==== Front
BMJ OpenBMJ OpenbmjopenbmjopenBMJ Open2044-6055BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR bmjopen-2018-023728corr110.1136/bmjopen-2018-023728corr1Correction1506Correction: treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes
 2019 13 9 2019 13 9 2019 9 9 e023728corr1© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2019This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlockedaccess-typefree
==== Body
Castrén S, Mäkelä N, Haikola J, et al. Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes. BMJ Open 2019;9:e023728. doi: 10.1136/bmjopen-2018-023728

This article was previously published with error in ‘Competing interests’ statement.

The correct ‘Competing interests’ statement is mentioned below:

SC, NM, JH, AHS and HA declare no conflict of interest in relation to this manuscript. RC is a full time employee and shareholder of Opiant Pharmaceuticals. MS is part-time employee, board member and shareholder of Clinical Research Services Turku—CRST Oy, a clinical contract research organisation for the pharmaceutical industry. Previous research on nasal naloxone NALPET-study (EudraCT-number 2015-002681-23) by MS and HA have received grant support from Opiant Pharmaceuticals.

